Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

NCT02082249 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02082249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02082249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
March 10, 2014
Completion date
October 31, 2019
Enrollment
30 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced parkinson's disease